Abstracts tagged "immunosuppressants and uveitis"

Abstract Number: 1804 • 2018 ACR/ARHP Annual Meeting
Optimization Protocol for Adalimumab Treatment in Refractory Uveitis Due to Behçet’s Disease
José Luis Martín-Varillas¹, Belén Atienza-Mateo¹, Vanesa Calvo-Río², Diana Prieto Peña², Monica Calderón Goercke², Eva Peña Sainz-Pardo³, Emma Beltrán⁴, Juan Sánchez Bursón Sr.⁵, M. Victoria Hernández⁶, Alfredo Adan⁷, Marina Mesquida⁷, Marisa Hernández⁸, Elia Valls-Pascual⁹, Lucía Martínez-Costa⁹, Agusti Sellas-Fernandez¹⁰, Miguel Cordero-Coma¹¹, Manuel Díaz-Llopis¹², Roberto Gallego¹², David Salom¹², Norberto Ortego Centeno¹³, Jose L. García Serrano¹⁴, José-Luis Callejas-Rubio¹⁵, Jose M Herreras¹⁶, Angel Garcia-Aparicio¹⁷, Olga Maíz¹⁸, Ana Blanco¹⁹, Ignacio Torre-Salaberri²⁰, David Diaz-Valle²¹, Esperanza Pato Cour²², Elena Aurrecoechea²³, Miguel A. Caracuel²⁴, Fernando Gamero²⁵, Enrique Minguez²⁶, Carmen Carrasco-Cubero²⁷, Alejandro Olivé-Marqués²⁸, Oscar Ruiz Moreno²⁹, Javier Manero²⁹, Julio Vázquez³⁰, Santiago Muñoz Fernandez³¹, Myriam Gandía³², Esteban Rubio-Romero³³, Francisco Toyos³⁴, Francisco Javier López Longo³⁵, Joan Miquel Nolla³⁶, Marcelino Revenga Martínez³⁷, Javier Loricera³, Rosalía Demetrio-Pablo³, Enar Pons¹, José Luis Hernández³, Miguel Angel González-Gay³ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, ⁵Rheumatology, Hospital de Valme. Sevilla. Spain, Sevilla, Spain, ⁶Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁷Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁸Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁹Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ¹⁰Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ¹¹Ophthalmology, Hospital de León. Spain, León, Spain, ¹²Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹³Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ¹⁴Ophthalmology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ¹⁵Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ¹⁶Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, ¹⁷Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, ¹⁸Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, ¹⁹Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, ²⁰Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ²¹Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ²²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²³Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, ²⁴Hospital de Córdoba, Córdoba, Spain., Córdoba, Spain, ²⁵Rheumatology, Hospital San Pedro Alcántara. Cáceres. Spain, Cáceres, Spain, ²⁶Ophthalmology, Hospital Clínico de Zaragoza. Spain, Zaragoza, Spain, ²⁷Hospital de Mérida. Spain, Mérida, Spain, ²⁸Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁹Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ³⁰Rheumatology, Hospital de Ferrol. La Coruña. Spain, La Coruña, Spain, ³¹Hospital Universitario Infanta Sofía. Madrid. Spain, San Sebastián de los Reyes (Madrid), Spain, ³²Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, ³³Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, ³⁴Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ³⁵Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³⁶Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³⁷Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain
Background/Purpose: Uveitis is the most common ocular manifestation in Behçet Disease (BD), which can cause irreversible blindness. Once the efficacy, safety and cost-effectiveness of Adalimumab…
Abstract Number: 1155 • 2017 ACR/ARHP Annual Meeting
Impact of Adalimumab on Immunosuppressant Use in Patients with Active and Inactive Non-Infectious Intermediate, Posterior, or Pan-Uveitis in the Ongoing Open Label Study: Visual-III
Sergio Schwartzman¹, Irene Van der Horst-Bruinsma², Alfredo Adan³, Hiroshi Goto⁴, Koju Kamoi⁵, Martina Kron⁶, Alexandra P. Song⁷, Kevin Douglas⁷, Sophia Pathai⁸ and C. Stephen Foster⁹, ¹Hospital for Special Surgery, New York, NY, ²Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁴Tokyo Medical University, Tokyo, Japan, ⁵Tokyo Medical and Dental University, Tokyo, Japan, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Ltd, Maidenhead, United Kingdom, ⁹Massachusetts Eye Research and Surgery foundation and Harvard Medical School, Boston, MA
Background/Purpose: The morbidity associated with the use of immunosuppressants is well described in patients (pts) with autoimmune ophthalmic disease and presents a challenge to treating…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].